Brand-name latanoprost — Competitive Intelligence Brief

Brand-name latanoprost (Brand-name latanoprost) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prostaglandin F analog. Area: Ophthalmology.

marketed Prostaglandin F analog FP prostaglandin receptor Ophthalmology Small molecule

Target snapshot

Brand-name latanoprost (Brand-name latanoprost) — CHU de Quebec-Universite Laval. Latanoprost is a prostaglandin F analog that binds to the prostaglandin F (FP) receptor to increase uveoscleral outflow of aqueous humor, thereby lowering intraocular pressure.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Brand-name latanoprost TARGET	Brand-name latanoprost	CHU de Quebec-Universite Laval	marketed	Prostaglandin F analog	FP prostaglandin receptor
Travoprost/timolol fixed combination, travoprost	Travoprost/timolol fixed combination, travoprost	Aristotle University Of Thessaloniki	marketed	Prostaglandin analog / beta-blocker combination	FP prostaglandin receptor (travoprost); beta-adrenergic receptors (timolol)
Latanoprost plus adjunctive glaucoma medication	Latanoprost plus adjunctive glaucoma medication	Sight Sciences, Inc.	marketed	Prostaglandin analog with adjunctive glaucoma agent	FP prostaglandin receptor (latanoprost component); adjunctive target unknown
travoprost, latanoprost, or bimatoprost	travoprost, latanoprost, or bimatoprost	Robin, Alan L., M.D.	marketed	Prostaglandin F receptor agonist	FP prostaglandin receptor
Apo-Latanoprost	Apo-Latanoprost	Dr. David Yan	marketed	Prostaglandin F analog	Prostaglandin F receptor (FP receptor)
Preservative-free bimatoprost	Preservative-free bimatoprost	Association for Innovation and Biomedical Research on Light and Image	marketed	Prostaglandin F analog	Prostaglandin F (FP) receptor
IOPIZE© Latanoprost eyedrops	IOPIZE© Latanoprost eyedrops	University of Catanzaro	marketed	Prostaglandin F analog	Prostaglandin F receptor (FP receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prostaglandin F analog class)

1. Allergan · 8 drugs in this class
2. CHU de Quebec-Universite Laval · 2 drugs in this class
3. Association for Innovation and Biomedical Research on Light and Image · 2 drugs in this class
4. Kasr El Aini Hospital · 1 drug in this class
5. Merck Sharp & Dohme LLC · 1 drug in this class
6. Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in this class
7. Post Graduate Institute of Medical Education and Research, Chandigarh · 1 drug in this class
8. SpyGlass Pharma, Inc. · 1 drug in this class
9. Tun Hussein Onn National Eye Hospital · 1 drug in this class
10. Universitaire Ziekenhuizen KU Leuven · 1 drug in this class